FRINK Linked Data Fragments server

Matches in Wikidata for { <http://www.wikidata.org/entity/Q37625849> ?p ?o ?g. }

• Q37625849 description "article científic" @default.
• Q37625849 description "article scientifique" @default.
• Q37625849 description "articolo scientifico" @default.
• Q37625849 description "artigo científico" @default.
• Q37625849 description "artículu científicu espublizáu en 2013" @default.
• Q37625849 description "bilimsel makale" @default.
• Q37625849 description "scientific article published on 15 October 2013" @default.
• Q37625849 description "vedecký článok" @default.
• Q37625849 description "vetenskaplig artikel" @default.
• Q37625849 description "videnskabelig artikel" @default.
• Q37625849 description "vědecký článek" @default.
• Q37625849 description "wetenschappelijk artikel" @default.
• Q37625849 description "wissenschaftlicher Artikel" @default.
• Q37625849 description "наукова стаття, опублікована в жовтні 2013" @default.
• Q37625849 description "научни чланак" @default.
• Q37625849 description "գիտական հոդված հրատարակված 2013 թվականի հոկտեմբերի 15-ին" @default.
• Q37625849 description "مقالة علمية نشرت في 15 أكتوبر 2013" @default.
• Q37625849 name "Sequence-dependent combination therapy with doxorubicin and a survivin-specific small interfering RNA nanodrug demonstrates efficacy in models of adenocarcinoma." @default.
• Q37625849 name "Sequence-dependent combination therapy with doxorubicin and a survivin-specific small interfering RNA nanodrug demonstrates efficacy in models of adenocarcinoma." @default.
• Q37625849 name "Sequence-dependent combination therapy with doxorubicin and a survivin-specific small interfering RNA nanodrug demonstrates efficacy in models of adenocarcinoma." @default.
• Q37625849 type Item @default.
• Q37625849 label "Sequence-dependent combination therapy with doxorubicin and a survivin-specific small interfering RNA nanodrug demonstrates efficacy in models of adenocarcinoma." @default.
• Q37625849 label "Sequence-dependent combination therapy with doxorubicin and a survivin-specific small interfering RNA nanodrug demonstrates efficacy in models of adenocarcinoma." @default.
• Q37625849 label "Sequence-dependent combination therapy with doxorubicin and a survivin-specific small interfering RNA nanodrug demonstrates efficacy in models of adenocarcinoma." @default.
• Q37625849 prefLabel "Sequence-dependent combination therapy with doxorubicin and a survivin-specific small interfering RNA nanodrug demonstrates efficacy in models of adenocarcinoma." @default.
• Q37625849 prefLabel "Sequence-dependent combination therapy with doxorubicin and a survivin-specific small interfering RNA nanodrug demonstrates efficacy in models of adenocarcinoma." @default.
• Q37625849 prefLabel "Sequence-dependent combination therapy with doxorubicin and a survivin-specific small interfering RNA nanodrug demonstrates efficacy in models of adenocarcinoma." @default.
• Q37625849 P1433 Q37625849-A3BAFB47-7BA7-43BB-A73F-9C58D68EAC4D @default.
• Q37625849 P1476 Q37625849-C068548C-5FF3-4F4C-AC8F-E4FF4334395A @default.
• Q37625849 P2093 Q37625849-051D4C82-DDFB-4071-80FD-3B3817F33C58 @default.
• Q37625849 P2093 Q37625849-3CCF01B0-F75F-4369-91AB-6428A2D1A8C8 @default.
• Q37625849 P2093 Q37625849-6F2F3058-5D08-4067-BD0C-D6F41E4463E9 @default.
• Q37625849 P2093 Q37625849-C0CCC1D4-E1C4-4B69-9262-84FBAF84A7FE @default.
• Q37625849 P2093 Q37625849-EB877090-5441-42E8-9266-81878AE22D40 @default.
• Q37625849 P2860 Q37625849-0827D9D5-B5AA-4228-9BC5-9548EACED425 @default.
• Q37625849 P2860 Q37625849-092FE968-2803-47CB-B4BA-E4E36EA0DA52 @default.
• Q37625849 P2860 Q37625849-0B017C18-63E9-4BD3-AF59-90889CC2857B @default.
• Q37625849 P2860 Q37625849-23D74060-033D-4639-9D26-FA6219D6B47A @default.
• Q37625849 P2860 Q37625849-32525C46-1E17-49F1-8711-23D7396B5809 @default.
• Q37625849 P2860 Q37625849-3DC9BC7F-1D34-4F96-A49C-E82DCD50BA70 @default.
• Q37625849 P2860 Q37625849-3DF5B3F7-A8EC-49D6-B084-9A735BDBD446 @default.
• Q37625849 P2860 Q37625849-40BEB167-FC56-4AA6-994D-492FA92CABC1 @default.
• Q37625849 P2860 Q37625849-4D8AB0F4-9F76-47E3-A02A-13569E798712 @default.
• Q37625849 P2860 Q37625849-553C6093-4235-4955-9005-DAB3800868F5 @default.
• Q37625849 P2860 Q37625849-6E8B71B6-86C5-4CC2-9431-129951C8AB68 @default.
• Q37625849 P2860 Q37625849-7CDCE8B3-ED43-4AB1-B2D0-9C5DD5A0A0EB @default.
• Q37625849 P2860 Q37625849-86C790D7-F31C-4A90-A5F2-DBA3806F2E51 @default.
• Q37625849 P2860 Q37625849-8FABE265-6708-4478-A9CD-3DF6AA2BE627 @default.
• Q37625849 P2860 Q37625849-9D4DA88F-16C0-440F-B743-0C5B45BA50AC @default.
• Q37625849 P2860 Q37625849-A15A7BC2-B7E6-47B4-8B56-0E6B034ED591 @default.
• Q37625849 P2860 Q37625849-B82847B8-A892-4A14-ACE7-6ADD2A62AEA6 @default.
• Q37625849 P2860 Q37625849-BC204C8D-21CC-4901-9BD4-A6414B6667BC @default.
• Q37625849 P2860 Q37625849-BFF35096-950E-4143-887E-F7F1FBEB5098 @default.
• Q37625849 P2860 Q37625849-C5B5C9FE-DC60-46A2-9305-CE81C82B6A88 @default.
• Q37625849 P2860 Q37625849-CAFB276B-14C2-48D6-89A3-7BBDF7205D43 @default.
• Q37625849 P2860 Q37625849-D3273459-CE9A-40AE-AB4E-94984DEC5A28 @default.
• Q37625849 P2860 Q37625849-D4D92D76-F2E6-40B7-A982-087E90807BCB @default.
• Q37625849 P2860 Q37625849-DCEB5B2E-F7F8-4481-839B-7BAD12790ADF @default.
• Q37625849 P2860 Q37625849-DE70ABFD-C482-431B-9530-8C32504B4D09 @default.
• Q37625849 P2860 Q37625849-E368A3F0-F434-49D5-BABA-B5CB10532456 @default.
• Q37625849 P2860 Q37625849-EBC01249-6B50-4CA7-AA9B-EF1F192DD78E @default.
• Q37625849 P2860 Q37625849-ED034397-238E-42CB-9911-3EA83A379865 @default.
• Q37625849 P2860 Q37625849-EEF80E83-0D4E-420D-8CA5-7CEB2971A266 @default.
• Q37625849 P304 Q37625849-B5755727-334C-4F47-81BB-0AFE07F55B9F @default.
• Q37625849 P31 Q37625849-BF370468-D842-4E94-BBAC-4F7A81A84E55 @default.
• Q37625849 P356 Q37625849-26442DAD-345C-4BF1-AF63-E68C24E4683E @default.
• Q37625849 P407 Q37625849-554B2795-3FA7-4240-B442-85280024E26F @default.
• Q37625849 P433 Q37625849-F65DD640-2C6C-462D-96FD-DEB5AE0EC41A @default.
• Q37625849 P478 Q37625849-7C30240E-929F-4D6D-8D56-7B228AB73019 @default.
• Q37625849 P50 Q37625849-48B21098-47A9-4F9D-A57F-E71B87B842BA @default.
• Q37625849 P50 Q37625849-CC3D8CFD-02C8-453B-BE97-AD160D6B7FF6 @default.
• Q37625849 P577 Q37625849-5ED7DA3F-D5EE-4C0A-86B1-9CEC540AAFEB @default.
• Q37625849 P698 Q37625849-E69195F8-BA85-4EA1-BCEF-B475DB08D1F3 @default.
• Q37625849 P921 Q37625849-3FBD1527-95A9-46E4-8AEF-FD6866429B2E @default.
• Q37625849 P921 Q37625849-9ED47995-277D-40B4-AB68-824C6F70B3CA @default.
• Q37625849 P932 Q37625849-DE945FE2-5EA4-4E9C-874B-EAE03587D659 @default.
• Q37625849 P356 IJC.28499 @default.
• Q37625849 P698 24114765 @default.
• Q37625849 P1433 Q332492 @default.
• Q37625849 P1476 "Sequence-dependent combination therapy with doxorubicin and a survivin-specific small interfering RNA nanodrug demonstrates efficacy in models of adenocarcinoma" @default.
• Q37625849 P2093 "Alana W Ross" @default.
• Q37625849 P2093 "Masashi Uchida" @default.
• Q37625849 P2093 "Mehmet V Yigit" @default.
• Q37625849 P2093 "Subrata K Ghosh" @default.
• Q37625849 P2093 "Zdravka Medarova" @default.
• Q37625849 P2860 Q24322614 @default.
• Q37625849 P2860 Q28291799 @default.
• Q37625849 P2860 Q28300339 @default.
• Q37625849 P2860 Q33939126 @default.
• Q37625849 P2860 Q34168738 @default.
• Q37625849 P2860 Q34656854 @default.
• Q37625849 P2860 Q36491426 @default.
• Q37625849 P2860 Q36612156 @default.
• Q37625849 P2860 Q36623798 @default.
• Q37625849 P2860 Q37078708 @default.
• Q37625849 P2860 Q37324196 @default.
• Q37625849 P2860 Q37372203 @default.
• Q37625849 P2860 Q37471909 @default.
• Q37625849 P2860 Q39187136 @default.
• Q37625849 P2860 Q39195295 @default.

• next